Abstract:

The aim of this study was to combine a variety of biomarkers (such as structural MRI and CSF measures) in
subjects with mild cognitive impairment (MCI) using a novel multimodality fusion tool in order to extract nonredundant
information that is useful in predicting future cognitive decline. Alzheimer's Disease Neuroimaging
Initiative (ADNI) screening MRI and baseline CSF markers for 97 subjects with MCI (mean [sd] age 75 years [7.1],
54% ApoE4+, 35% FH+) were used. The CSF biomarkers included were tau, p-tau181P, and As1-42. 43 MCI subjects
converted to AD and 54 did not (as of October 19, 2010). Converters did not differ from non-converters in mean
age, gender ratio, education, and tau level but had lower baseline delayed recall memory scores (p The results will identify any regions of the brain or specific tests that contribute unique information about the risk of
conversion from MCI to AD, some of which may not have been identified in other region-of-interest based studies.
The analyses are in progress and final results will be presented at the meeting.

Acknowledgment: Data used in preparation of this article were obtained from the Alzheimer's Disease
Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI
contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or
writing of this report. A complete listing of ADNI investigators can be found at http://loni.ucla.edu//ADNI//Collaboration//ADNI_Authorship_list.pdf.